Understanding the efficacy variables of an HIV vaccine trial

Affiliations

Comment

José Esparza. Lancet Infect Dis. 2012 Jul.

. 2012 Jul;12(7):499-500.

doi: 10.1016/S1473-3099(12)70117-2. Epub 2012 May 30.

¹ Global Health Program, Bill and Melinda Gates Foundation, Seattle, WA 98102, USA. Jose.Esparza@Gatesfoundation.org

No abstract available

Comment on

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.
Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, Khamboonruang C, Thongcharoen P, Morgan P, Benenson M, Paris RM, Chiu J, Adams E, Francis D, Gurunathan S, Tartaglia J, Gilbert P, Stablein D, Michael NL, Kim JH. Robb ML, et al. Lancet Infect Dis. 2012 Jul;12(7):531-7. doi: 10.1016/S1473-3099(12)70088-9. Epub 2012 May 30. Lancet Infect Dis. 2012. PMID: 22652344 Free PMC article. Clinical Trial.